Table 1.
Clinical characteristics of the study population.
| Cases (N = 25) |
Control (N = 25) |
P value | |
|---|---|---|---|
| Demographic variables | |||
| Age | 64.8 ± 10.8 | 65.0 ± 11.3 | 1 |
| Gender | 0.04 | ||
| Females | 7 (28%) | 14 (56%) | |
| Males | 18 (72%) | 11 (44%) | |
| Race∗ | 0.8 | ||
| White | 13 (54%) | 12 (48%) | |
| Black | 11 (46%) | 12 (48%) | |
| Clinical variables | |||
| Smoking | 10 (40%) | 10 (40%) | 1 |
| Diabetes | 8 (32%) | 9 (36%) | 1 |
| BMI | 29.6 ± 4.8 | 25.3 ± 4.7 | 0.00 |
| Hypertension | 16 (64%) | 14 (56%) | 0.6 |
| Mean SBP (mm Hg) | 135.4 ± 19.2 | 127.4 ± 16.7 | 0.1 |
| Mean DBP (mm Hg) | 75.8 ± 13.0 | 74.0 ± 10.3 | 0.6 |
| Hypercholesteremia | 14 (56%) | 10 (40%) | 0.4 |
| Medications | |||
| Betablocker | 15 (60%) | 10 (40%) | 0.3 |
| ACEI | 12 (48%) | 9 (36%) | 0.6 |
| ARB | 4 (16%) | 1 (4%) | 0.4 |
| Diuretic | 4 (16%) | 8 (32%) | 0.3 |
| Statin | 14 (56%) | 16 (64%) | 0.8 |
∗1 (4%) Asian in each group; HFpEF: heart failure with preserved ejection fraction; DD: diastolic dysfunction; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blocker.